Urine Test for Bladder Cancer Could Aid Early Detection
A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.
Managed Care Minute: February 28, 2015
A one-minute look at managed care news during the week of February 23, 2015, including another step by CMS toward a quality-based payment system and more predictions on the outcomes of King v. Burwell
Opdivo Gets Priority Review for NSCLC
BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.
AJMC Panel Sees Advantages in FDA Regulation of Molecular Diagnostic Tests for Cancer CareThe American Journal of Managed Care
convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA’s plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.
For Stakeholders in Immuno-Oncology, Is the Third Time the Charm?Evidence-Based Oncology
, an indexed publication of The American Journal of Managed Care
, devotes its current issue to immuno-oncology and the interests of many stakeholders. In a commentary that draws on 30 years of waiting on the promise of immuno-oncology, Bruce Feinberg, DO, outlines the key issues facing payers, oncologists, policymakers and patients themselves.
Basket Trials Have FDA Support, But Will They Deliver?
Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.
Medical ID Theft on the Rise
Medical identity theft jumped 22% last year as more US health data becomes electronic and easier for cyber criminals to steal from doctors’ offices, hospitals and insurers.
CMS Extends Medicare Meaningful Use Deadline
Eligible healthcare professionals participating in the Medicare Electronic Health Record (EHR) Incentive Program 2014 reporting year will have additional time to attest to meaningful use, according to an announcement from CMS.
Cancer Prevention Could Begin With HIV-Infected Populations, Study Shows
The study, published in the current issue of the Journal of the National Cancer Institute
determined that the total cancer burden was highest among people in the 50-59 years age bracket, men who have sex with men, those living 5 or more years with AIDS, and non-Hispanic blacks. But the largest excess burden was among people 15-29 years old.
NICE Rejects Provenge, Says Treatment is Not Cost-Effective
The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.